ROIV

SEC source: 0001140361-25-037740 · form4.xml · nonDerivative · entry 7

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,860,120

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-037740 · form4.xml · nonDerivative · entry 6

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,679,261

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-037740 · form4.xml · nonDerivative · entry 5

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,572,130

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-037740 · form4.xml · derivative · entry 14

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,457,382

Underlying: Common Stock · 19,141 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

SEC source: 0001140361-25-037740 · form4.xml · derivative · entry 13

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 235,426

Underlying: Common Stock · 24,900 shares

Expires 2027-11-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of October 16, 2017. These options are fully vested.

SEC source: 0001140361-25-037740 · form4.xml · derivative · entry 12

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,054,528

Underlying: Common Stock · 127,355 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.

SEC source: 0001140361-25-037740 · form4.xml · nonDerivative · entry 4

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,504,959

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

SEC source: 0001140361-25-037740 · form4.xml · nonDerivative · entry 3

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,676,355

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-037740 · form4.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,657,214

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-037740 · form4.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,632,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-036831 · form4.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 389,508

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001140361-25-035890 · form4.xml · nonDerivative · entry 7

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,504,959

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

SEC source: 0001140361-25-035890 · form4.xml · derivative · entry 10

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,476,523

Underlying: Common Stock · 100,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

SEC source: 0001140361-25-035890 · form4.xml · derivative · entry 9

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,576,523

Underlying: Common Stock · 462,374 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

SEC source: 0001140361-25-035890 · form4.xml · nonDerivative · entry 6

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,115,959

F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024.

SEC source: 0001140361-25-035890 · form4.xml · nonDerivative · entry 5

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,215,959

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

SEC source: 0001140361-25-035890 · form4.xml · nonDerivative · entry 4

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,532,141

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-035890 · form4.xml · nonDerivative · entry 3

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,432,141

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-035891 · form4.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 391,849

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001140361-25-035890 · form4.xml · derivative · entry 8

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,038,897

Underlying: Common Stock · 1,000,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

SEC source: 0001140361-25-035890 · form4.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,969,767

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

SEC source: 0001140361-25-035890 · form4.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,653,585

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-035435 · form4.xml · nonDerivative · entry 1

Gline Matthew · CIK 0001750094 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,287,081

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range.

SEC source: 0001140361-25-034929 · form4.xml · derivative · entry 3

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,726

Underlying: Common Shares · 33,726 shares

Expires 2035-09-09

F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0001140361-25-034929 · form4.xml · nonDerivative · entry 2

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,848

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

SEC source: 0001140361-25-034929 · form4.xml · nonDerivative · entry 1

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,509

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0001140361-25-034931 · form4.xml · derivative · entry 3

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,726

Underlying: Common Shares · 33,726 shares

Expires 2035-09-09

F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0001140361-25-034931 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,162

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

SEC source: 0001140361-25-034931 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,205

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0001140361-25-034934 · form4.xml · derivative · entry 2

MANCHESTER KEITH S · CIK 0001244828 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,726

Underlying: Common Shares · 33,726 shares

Expires 2035-09-09

F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0001140361-25-034934 · form4.xml · nonDerivative · entry 1

MANCHESTER KEITH S · CIK 0001244828 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,948,403

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0001140361-25-034933 · form4.xml · derivative · entry 3

Gold Daniel Allen · CIK 0001832142 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,726

Underlying: Common Shares · 33,726 shares

Expires 2035-09-09

F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0001140361-25-034933 · form4.xml · nonDerivative · entry 2

Gold Daniel Allen · CIK 0001832142 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,965,894

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

SEC source: 0001140361-25-034933 · form4.xml · nonDerivative · entry 1

Gold Daniel Allen · CIK 0001832142 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,971,164

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0001140361-25-034932 · form4.xml · derivative · entry 3

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,726

Underlying: Common Shares · 33,726 shares

Expires 2035-09-09

F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0001140361-25-034932 · form4.xml · nonDerivative · entry 2

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,963

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

SEC source: 0001140361-25-034932 · form4.xml · nonDerivative · entry 1

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,900

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0001140361-25-034930 · form4.xml · derivative · entry 3

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,726

Underlying: Common Shares · 33,726 shares

Expires 2035-09-09

F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0001140361-25-034930 · form4.xml · nonDerivative · entry 2

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,912

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

SEC source: 0001140361-25-034930 · form4.xml · nonDerivative · entry 1

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,194

F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.

SEC source: 0002007997-25-000007 · primary_doc.xml · nonDerivative · entry 3

Ramaswamy Vivek · CIK 0001635075 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,508,359

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $13.04, inclusive.

SEC source: 0002007997-25-000007 · primary_doc.xml · nonDerivative · entry 2

Ramaswamy Vivek · CIK 0001635075 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,894,175

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive.

SEC source: 0002007997-25-000007 · primary_doc.xml · nonDerivative · entry 1

Ramaswamy Vivek · CIK 0001635075 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,089,108

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $12.71, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4.

SEC source: 0001140361-25-033687 · form4.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 393,978

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001140361-25-032405 · form4.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 396,318

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001140361-25-032404 · form4.xml · derivative · entry 4

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,038,897

Underlying: Common Stock · 100,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

SEC source: 0001140361-25-032404 · form4.xml · nonDerivative · entry 3

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,653,585

F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024.

SEC source: 0001140361-25-032404 · form4.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,753,585

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-032404 · form4.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,653,585

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001140361-25-028452 · form4.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,660,636

F1 · shares: Reflects an award of restricted stock units with respect to Common Shares ("RSUs"), with a vesting commencement date of May 20, 2025, which service-vest (i) 25% on the first anniversary of the vesting commencement date and (ii) in 12 successive equal quarterly installments thereafter, subject to the reporting person's continuous service through each vesting date.